Program Volume: 2024
HEMATOLOGY, ONCOLOGY & STEM CELL TRANSPLANT
RESEARCH HIGHLIGHTS
12,000 patient visits
12% telemedicine visits
Riley Children’s is engaged in leading-edge pediatric oncology and hematology clinical trials through membership in the following organizations: ■ Children’s Oncology Group ■ Developmental Therapeutics/Pediatric Early Phase Clinical Trials Network ■ BigTen Clinical Trials Network
Expert hematologists, oncologists and stem cell transplant specialists at Riley Children’s Health combine leading-edge medicine with holistic, personalized care to treat children with cancer and blood disorders. With access to the latest clinical trials and therapeutic options, our skilled specialists treat the full spectrum of pediatric cancers, including aggressive disease and cancers that are no longer responsive to conventional therapy.
By condition, Riley Children’s treats more than: ■ 1,500 hematology patients ■ 450 leukemia patients ■ 420 sickle cell patients ■ 270 brain tumor patients ■ 120 lymphoma patients ■ 80 bone tumor patients ■ 70 kidney tumor patients ■ 60 sarcoma patients ■ 35 retinoblastoma patients ■ 20 neuroblastoma patients ■ 20 germ cell tumor patients ■ 10 liver tumor patients
■ Therapeutic Advances in Childhood Leukemia ■ Pacific Pediatric Neuro-Oncology Consortium ■ Neurofibromatosis Clinical Trials Consortium ■ Consortium of Investigators of Vascular Anomalies ■ North American Consortium for Histiocytosis
TOP DISTINCTIONS
Premier programs
Advanced therapies and procedures ■ CAR-T trials for leukemia (PLAT Phase I and Phase II trials) ■ Gene therapy for beta thalassemia and sickle cell disease (Bluebird Bio and Vertex) ■ NK cell infusions following stem cell transplant Our program is accredited or certified by: ■ Foundation for the Accreditation of Cellular Therapy (FACT) ■ Association for the Advancement of Blood & Biotherapies (AABB) ■ American Society for Histocompatibility & Immunogenetics (ASHI) ■ National Cancer Institute Comprehensive Cancer Center ■ Health Care Financing Administration
■ Home to the only pediatric stem cell transplant and CAR-T cell therapy programs in Indiana ■ Part of the only National Cancer Institute-designated Comprehensive Cancer Center in Indiana ■ Largest comprehensive sickle cell program in Indiana: – Only National Institutes of Health-funded telemedicine program in the nation for pediatric sickle cell disease – One of 40 institutions in the National Alliance of Sickle Cell Disease Centers – Only Lifespan Sickle Cell Disease Center of Excellence in the state ■ Among the 10% of Children’s Oncology Group (COG) members that have early access to clinical trials and new treatments through the COG Phase I and Pilot Consortium ■ One of the only children’s hospitals in the nation with a multidisciplinary treatment program for neurofibromatosis ■ Sole Indiana program (and one of the few regionally) to offer an experimental testicular tissue cryopreservation protocol
■ Precision Genomics Program ■ Neurofibromatosis Program ■ Stem Cell/Immunotherapy Program ■ Comprehensive Bleeding Program and Women and Girls Blood Disorder Clinic of Excellence ■ Thrombosis and Thrombophilia Program ■ Sickle Cell Disease Program (includes a multidisciplinary program for high-risk patients) ■ Onco-Fertility Program ■ Survivorship Program ■ Developmental Therapeutics Program ■ Adolescent and Young Adult Oncology Program
■ Sickle Cell Transplant Advocacy and Research Alliance ■ Pediatric Transplantation and Cellular Therapy Consortium ■ Bone Marrow Transplant Clinical Trials Network ■ North American Pediatric Aplastic Anemia Consortium ■ Globin Regional Data and Discovery Network (Sickle cell registry)
> View active hematology and oncology clinical trials at Riley Children’s.
We offer co-location of subspecialists to provide convenient and accessible care to individuals living with sickle cell disease.
NOTABLE PUBLICATIONS
Blood: November 2024 Neurocognitive screening and neighborhood impact for children and adolescents with sickle cell disease Cancer Discovery: September 2024 Efficacy of the allosteric MEK inhibitor trametinib in relapsed and refractory juvenile myelomonocytic leukemia: A report from the Children’s Oncology Group Blood: November 2024
Our program is affiliated with the Brown Center for Immunotherapy at IU School of Medicine (offering access to novel immunotherapy and gene therapy clinical trials only available at IU) and the highly regarded Indiana University Gene Therapy Testing Laboratory .
Neurofilament light chain: A potential biomarker for chemotherapy induced peripheral neuropathy in pediatric adolescent young adults Lead author: Jennifer A. Belsky, DO, MS Neuro-Oncology: June 2024 OTHR-27. Narrative medicine applied: A study elucidating how one neuro-oncology
DIVISION CHIEF Brian D. Weiss, MD Nora Letzter Professor of Pediatrics, IU School of Medicine > Connect with Dr. Weiss on Doximity.
100+ research publications in 2024
team grapples with distress OUR TEAM ALSO PUBLISHED IN: Psycho-Oncology Pediatric Quality and Safety Pediatric Blood and Cancer
34 board certified physicians
See full team member list >
80% overall
93% for leukemia patients
Five-Year Survival Rates
Annual Report 2024 – 2025
Refer a patient online
317.944.2143
Made with FlippingBook flipbook maker